World Wires · story 92795 · official · 1 source(s)

FDA Approves First Plasmid DNA-based Immunotherapy for RRP

The U.S. Food and Drug Administration granted accelerated approval for Voceryq to treat adults with recurrent respiratory papillomatosis.

Open in the desk

Coverage

• FDA Approves First Plasmid DNA-based Immunotherapy for RRP FDA press announcements · tier A · clear net · 2026-10-30 20:32 UTC

What this site indexes